EyePoint Pharmaceuticals, Inc.

Symbol: EYPT




Market price today

  • -5.6616

    P/E Ratio

  • -0.1192

    PEG Ratio

  • 676.18M

    MRK Cap

  • 0.00%

    DIV Yield

EyePoint Pharmaceuticals, Inc. (EYPT) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Jay S. Duker M.D.
Full-time employees:144
Address:480 Pleasant Street

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

General Outlook

In simple terms, EyePoint Pharmaceuticals, Inc. has 35.309 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.806% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -2.297%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -3.404%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.724% return, is a testament to EyePoint Pharmaceuticals, Inc.'s adeptness in optimizing resource deployment. EyePoint Pharmaceuticals, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -1.380%. Furthermore, the proficiency of EyePoint Pharmaceuticals, Inc. in capital utilization is underscored by a remarkable -0.803% return on capital employed.

Stock Prices

EyePoint Pharmaceuticals, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $6.67, while its low point bottomed out at $5.98. This variance in figures offers investors a lucid insight into the roller-coaster ride that is EyePoint Pharmaceuticals, Inc.'s stock market.
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2023?

There are stock number shares outstanding of EyePoint Pharmaceuticals, Inc. (EYPT) on the NASDAQ in 2023.

What is P/E ratio of enterprise in 2023?

The current P/E ratio of enterprise is -5.662 in 2023.

What is the ticker symbol of EyePoint Pharmaceuticals, Inc. stock?

The ticker symbol of EyePoint Pharmaceuticals, Inc. stock is EYPT.

What is company IPO date?

IPO date of EyePoint Pharmaceuticals, Inc. is 2005-01-27.

What is company current share price?

Current share price is 19.150 USD.

What is stock market cap today?

The market cap of stock today is 676175010.000.

What is PEG ratio in 2023?

The current -0.119 is -0.119 in 2023.

What is the number of employees in 2023?

In 2023 the company has 144.